Articles Posted in Dangerous Products

Published on: September 29, 2025

2.9 Million Electric Motors of Air Vent, Inc. Attic Fans Recalled

attic-5684674_640-e1757185095942 On August 28 of this year, certain electric motors found in Air Vent’s gable- and roof-mounted attic fans sold from August 2003-December 2013 were recalled using the fast track method. Around 2.9 million electric motors are affected by the recall. The reason for the recall is that the motor’s safety cutoff could present a chance of short circuit and fire danger while the attic fan is being used. If you or a loved one was injured or died as a result of a fire involving your attic fan, you should call the seasoned Chicago-based product liability lawyers of Moll Law Group about whether you have grounds to sue for damages. Billions have been recovered in product liability cases around the country with which we’ve been involved.

Call Moll Law Group About an Attic Fan Lawsuit

The attic fans with affected motors, distributed by Air Vent, were sold between August 2003-December 2013 at Lowe’s, Beacon, ABC Supply, and other stores and wholesalers around the country. They sold for around $74 and $92.

The attic fan model numbers impacted by the recall are DOW-136-0-34-XIN, DOW-136-0-26-XIN, DOW-136-0-40-XIN, DOW-136-0-40-XIN-3/4”, and D-RE-PSC-127/20-4P1SP. The affected motors have a special vent pattern on the motor end bells. There have been 159 reports of fire or burning incidents related to the recalled attic fan motors, but so far, there haven’t been reports of injuries

Continue reading →

Published on: September 9, 2025

Warnings About a New Vape Shop Hazard, 7-OH

By Moll Law Group

urban-6712756_640-e1757035392842 A new danger has emerged in vape shops and at gas stations and corner stores. Health officials warn that a concentrated kratom byproduct called 7-OH is being produced and marketed in ways that appeal to kids, and can be bought easily, even though it is believed to have effects and impacts similar to those of opioids. The 7-OH products are available to consumers in a range of forms and packages such as candy, fruit-flavored gummies, ice cream cones, drink mixes and shots, and tablets. Officials worry these products may represent the next stage of the opioid crisis. The FDA has taken steps to get 7-OH restricted. If you or your child was harmed by 7-OH, you should call the seasoned Chicago-based product liability lawyers of Moll Law Group. Billions have been recovered in product liability lawsuits around the country with which we’ve been involved.

Call Moll Law Group About Your Potential Claim

On July 29, the United States Department of Health and Human Services (HHS) let consumers know that the U.S. Food and Drug Administration (FDA) is taking steps to try to stop the availability of 7-OH. There’s been a recommendation to restrict some of the products that contain 7-OH under the Controlled Substances Act, for instance. Further, the FDA has provided consumers with educational materials, health care providers with a letter, and a scientific assessment that indicates people can develop opioid addiction when they use 7-OH products repeatedly or over a long time. The FDA has also sent warning letters to various businesses for illegal marketing of products containing the addictive substance.

7-OH, which appeared in products starting around 2023, is also referred to as 7-hydroxymitragynine, 7-hydroxy, 7-OHMG, 7-HMG, and 7. It is one of two psychoactive components that occurs naturally in kratom, which is a plant whose leaves were sold for medicinal and recreational purposes throughout the 2000s. There are only small quantities of 7-OH in kratom, but the products that are sold in cape shops have significant quantities of 7-OH; it’s believed that synthetic steps are taken to change another psychoactive component of kratom, one that exists in greater quantities, into 7-OH.

Continue reading →

Published on: August 26, 2025

Consumer Advocacy Groups Oppose Elimination of the CPSC

By Moll Law Group

job-5382501_1280-e1754760475318 The Trump Administration has proposed elimination of the Consumer Product Safety Commission (CPSC), a bipartisan independent agency created by Congress that handles numerous product safety questions. An elimination of the agency would take crucial data-driven safety rules that protect people around the country from dangerous and defective products and immediately leave those rules vulnerable to political aims. The CPSC’s own 2026 budget request to Congress was the vehicle for the proposal of both agency elimination and an alarming reduction in consumer safety funding and staffing. This budget request, as well as an earlier leak of Administration documents that revealed a plan to get rid of the CPSC, have been strongly condemned by the Consumer Federation of America and other groups. There is still recourse if you or a loved one was injured by a defective or dangerous product. You should consult the seasoned product liability lawyers of Moll Law Group to determine whether you have a viable claim. Billions have been recovered in lawsuits with which we’ve been involved.

Talk to Moll Law Group About Your Defective Product Claim

The CPSC budget request proposes that CPSC functions be transferred to the Department of Health and Human Services (HHS). Meanwhile, the HHS is also experiencing a dramatic reduction in both funding and workforce. There have been layoffs, grant cancellations, and disruptions to public health programs around the country. In its criticism of the budget request for elimination, the Consumer Federation stated that it was fantastical to think that a new assistant secretary position could effectively utilize HHS administrative and support functions in the face of HHS’s huge budget cuts. The budget request, it says, will impair the ability to discover, respond to, and ultimately stop dangerous products from entering homes.

There are also 121 consumer advocacy groups that have called on Congress to reject the plan to collapse CPSC into HHS on the grounds that moving the agency could delay and weaken oversight, including the taking of important safety actions around dangerous products. The groups have asked Congress to maintain CPSC’s independence in the interests of household safety, and they’ve also asked Congress to fully fund the original fiscal year 2026 budget request from CPSC rather than follow the transfer plan. With the funds from the original budget request, the CPSC could conduct detailed investigations of emerging dangers, inform the public more clearly about safety problems, modernize its outdated technologies, stop dangerous items at ports of entry, and improve enforcement of product safety laws.

Continue reading →

Published on: March 4, 2025

The FDA Makes Announcements Related to Smoking and Nicotine Addiction

By Moll Law Group

cigarette-7285317_640 2025 opened with announcements from the U.S. Food and Drug Administration (FDA) about cessation of smoking and the reduction of nicotine addiction. The first of the two announcements was a Notice of Proposed Rulemaking. This would call for a reduction in nicotine in combustible tobacco products to levels that are not addictive. This has been requested by public health advocates since 2009’s Family Smoking Prevention and Tobacco Control Act, which authorized such a change. The agency has set out a comment period that from January 16 all the way to September 15 of this year. However, the other announcement had to do with authorizing 3 mg and 6 mg nicotine content in a broader range of flavors of 20 Zyn nicotine pouches, which seems potentially dangerous for children. If your child was harmed by a nicotine pouch or other addictive nicotine product, call the knowledgeable product liability lawyers of Moll Law Group.

Consult the Trustworthy Moll Law Group About Your Nicotine Claim

In a time when the harms of nicotine to the body and brain, particularly on youth brain development, are increasingly clear, it seems surprising that the FDA would authorize 20 Zyn nicotine pouches in multiple attention-grabbing flavors like Peppermint, Chill, Smooth, Citrus, and Cinnamon. The second announcement seems to cut against the general tendency of the FDA to try to spur smoking cessation, such as by calling for reductions of nicotine in other products.

The agency justifies the decision allowing for greater marketing efforts with the claim that adults who use Zyn have switched entirely to those products to consume nicotine rather than smoke cigarettes or obtain smokeless tobacco. It claims that the Zyn products have less deleterious chemicals than those other products. It also argues that it will keep an eye on Zyn marketing to make sure the manufacturer is complying with the nuances of the marketing order—Zyn isn’t allowed to promote these products to children or teens, and the marketing order can be rescinded for noncompliance.

Continue reading →

Published on: December 17, 2024

Oxbryta Litigation Has Commenced

By Moll Law Group

treatment-4099432_6402-e1734460206805 Recently, a medication for sickle cell disease, Oxbryta, was voluntarily recalled because it can cause complications and death. Litigation has begun against Pfizer Inc. and its subsidiary Global Therapeutics. One plaintiff, a patient who underwent treatment, has alleged that the companies should have known that administration of the sickle cell treatment could result in a patient’s death. According to that plaintiff, he suffered a higher rate of vaso-occlusive crisis after he used the medication. Pfizer denies that it acted irresponsibly. If you were harmed by Oxbryta, give the seasoned Chicago-based dangerous drug lawyers of Moll Law Group a call.

Call Moll Law Group About Your Oxbryta Claim

Oxbryta is a drug that was meant to alleviate sick cell disease symptoms. It was formulated to prevent hemoglobin polymerization; this, in turn, stops the sickling of red blood cells and improving the ability for hemoglobin to be oxygenated. In 2019, the Food and Drug Administration (FDA) accelerated its approval for those patients who are at least 12-years-old. In 2021, the FDA approved the drug for children with the minimum age for use being age 4. Unfortunately, once the drug was used in the real world, certain side effects were dire. One of the complications that arose in connection with the drug were vaso-occlusive crises, painful incidents where the sickled blood cells obstruct the flow of blood through a patient’s body. Some patients died as a result of these complications.

Pfizer recalled the drug across the world in September 2024, due to this real-world data that indicated Oxbryta’s risks are greater than its potential benefits. Patients and family members brought many lawsuits against Pfizer, and many of these claimed that Pfizer and its subsidiary had failed to provide adequate warnings as to these risks and complications. In plain terms, they are arguing that the company didn’t let them know about the risk of suffering vaso-occlusive crises and death and this prevented doctors and patients from making informed decisions about whether or not to take the drug.

Continue reading →

Published on: October 22, 2024

Brain Tumors Linked to Depo-Provera

By Moll Law Group

injection-4544448_640 The drug company Pfizer manufactures the popular form of contraception Depo-Provera. It’s a contraceptive administered via an injection every three months; it suppresses ovulation and thickens cervical mucus to block sperm’s ability to get to the egg. However, studies have shown that there is a link between increased risk of brain tumors and Depo Provera, and this has resulted in an increased uptick in danger drug lawsuits filed. If you were harmed by Depo-Provera, you should call the seasoned Chicago-based product liability lawyers of Moll Law Group. Billions have been recovered in cases with which we’ve been involved.

Consult Attorneys at Moll Law Group

Many patients use hormonal birth control. One of these methods is Depo-Provera, an intramuscular injection of medroxyprogesterone acetate, a synthetic form of progesterone, into a buttock or arm. It impacts reproduction. The chances of getting pregnant are reduced through the alteration of the uterine lining and stop of ovulation. It’s more than 99% effective if it’s routinely given on schedule.

Depo-Provera has been connected to a patient’s increased risk of meningioma, which is a kind of brain tumor. In fact, studies have revealed that long-term use of Depo-Provera markedly ups the chances of developing these kinds of tumors. Specifically, the British Medical Journal has indicated a 5.6-fold increase in risk of intracranial tumors due to Depo-Provera—which can cause brain pressure that requires invasive surgery that carries severe health problems and complications. You may be especially vulnerable if you’ve used Depo-Provera for a lengthy time. The symptoms of meningioma you should look out for include hearing loss, seizures, vision problems, persistent headaches, and weakness. It’s noteworthy that other progestogens like levonorgestrel intrauterine systems and dydrogesterone don’t seem associated with an increased risk.

Continue reading →

Published on: June 18, 2024

CPSC Reports that Off-Highway Vehicle Deaths Have Increased by 33%

By Moll Law Group

atv-e1718066265390 Off-highway vehicle use typically increases during the summer months. Recently, the Consumer Product Safety Commission issued its annual report about rising off-highway deaths and injuries. Among other things, the report revealed that minors under age 16, as well as adults between the ages of 45 and 54 have higher death rates in off-highway vehicles. Overall, there was a 33% increase in off-highway vehicle deaths in 2020 compared to 2019—these were the two most recent years for which there was data. Males were disproportionately affected. The CPSC chair Alex Hoehn-Saric has asked that safe riding be put first and that riders should wear a helmet with proper gear.

Call Moll Law Group About Your Off-Highway Vehicle Lawsuit

The CPSC report asks rider to take appropriate steps to avoid collisions. Leading causes of death in off-highway vehicles were crashes with other vehicles and stationary objects like trees. Often the occupants of vehicles would be thrown out of the vehicle during these collisions.

The report also informs us that children under age 12 constituted 44% of fatalities of children under 16. Additionally, adults older than 55 were affected; they made up 30% of related deaths.

Continue reading →

Published on: April 24, 2024

Eli Lilly Received Approval for New Weight Loss Drug Zepbound

By Moll Law Group

belly-2354_1280-e1712682579349-300x200 There has been a huge uptick in the demand for weight loss drugs and as a result of new drug approvals, the supply has been impacted. Last fall, the drug manufacturer Eli Lilly received approval from the Food and Drug Administration (FDA) for a new medication for chronic weight management. The drug is known as Zepbound, and at $1059.87 for a month’s supply, it is cheaper than Wegovy, which is manufactured by Eli Lilly’s competitor Novo Nordisk. However, much of the excitement of Zepbound and Wegovy fails to appreciate the risks associated with these drugs. If you are a patient who has been harmed by Zepbound, you should call the seasoned dangerous drug Chicago-based attorneys of Moll Law Group. We represent people harmed around the country and billions have been recovered in lawsuits with which we’ve had involvement.

Consult Moll Law Group About Your Weight Loss Drug Lawsuit

The use of diabetes drugs for weight loss has gained increasing public attention. Initially, the FDA wouldn’t allow Eli Lilly to market the diabetes drug Mounjaro for obesity, but late last year, it approved Zepbound, which is based on the same active ingredient. You should be aware, however, that there still questions about long-term health risks of using these drugs.

Zepbound, or tirzepatide, is given as an injection for chronic weight management in patients that are obese or overweight with an additional weight-related condition. Around 70% of adults around the country are obese or overweight; being able to lose 5%-10% of their weight has been linked to a reduced danger of suffering cardiovascular disease. The same drug is marketed under the trade name Mounjaro for use by adults with type 2 diabetes mellitus to better their glucose levels. Mounjaro has been the subject of increasing numbers of product liability lawsuits brought by people who took the drug and allegedly experienced gallbladder and gastrointestinal complications necessitating further expensive medical treatment.

Continue reading →

Published on: May 23, 2023

Ivenix Infusion System Recall Issued Over Risk of Leaks

By Moll Law Group

treatment-ge2ec498b1_1280-e1683586667860 Recently, the United States Foods and Drug Administration (FDA) issued a recall for Fresenius’ Ivenix Infusion System. Over 1,500 infusion pumps have been found susceptible to leaks and electrical failures that can result in the pump turning off during a treatment that is normally lifesaving. These systems may be defective. If you were injured or a loved one died and you believe it was the result of an Ivenix infusion defect, you should call the seasoned Chicago-based product liability lawyers of Moll Law Group. We represent injured consumers nationwide. Billions have been recovered in lawsuits with which we’ve been involved.

Call Moll Law Group About Whether You Have an Infusion Lawsuit

The recalled system is a high-volume pump that hospital staff use to provide a patient with specific amounts of fluid to their veins, or beneath their skin, or in their spine. Patients who receive this care include adults, infants, children, teens, and neonates. The danger addressed by the recall is that the pump can leak fluids from the pump into what’s called the Administration Set Loading Area of the infusion system.

This poses a serious danger because that area is located by the Air detector, and when fluid hits the electrical parts of the infusion pump, it may go through an electrical short that leads the device to power down with so warning. There have been 14 reports arising out of this issue. No deaths were reported as of this writing, but officials have warned that delay of infusions to children who need them could cause serious injuries or deaths.

Continue reading →

Published on: April 11, 2023

Side Effects and Off Label Use of Ozempic

By Moll Law Group

hand-gb5c718cdb_640 Doctors have been concerned about off-label use of Ozempic due to the risks of suffering gallbladder disease in connection with the drug. If you suffered harm to your gallbladder or other injuries and suspect they are the result of taking Ozempic, you should call the experienced Chicago-based product liability lawyers of Moll Law Group. Billions have been recovered in dangerous drug lawsuits with which we’ve been involved across the state.

Call Moll Law Group About Your Claim

The prescription drug Ozempic is a liquid inside pre-filled disposable pens that is used to control the blood sugar of adult type 2 diabetes patients. Semaglutide is the active ingredient of Ozempic. There is no generic form provided of the drug.

Ozempic is injected beneath the skin. Generally, adults have been advised to combine Ozempic with lifestyle improvements. The drug also lowers the chance of suffering stroke or heart attack. However, the drug is not recommended for type 1 diabetics, those with diabetic ketoacidosis, or those who have had pancreatitis. And Ozempic’s connection to gallbladder trouble may make it risky to use.

Continue reading →